A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection

Phase 2

Completed

• Conditions: Cytomegalovirus Disease
• Interventions: Drug: NPC-21 Low dose; Drug: NPC-21 High dose; Drug: NPC-21 Placebo

• Registration Number: NCT04225923
• Lead Sponsor: Nobelpharma

Brief Summary

The primary objective is to assess the efficacy and safety of NPC-21 when administered prophylactically to cytomegalovirus (CMV) seronegative patients receiving a first kidney transplant from a CMV seropositive donor.

Detailed Description

This is a Phase 2, randomized, double-blind, placebo-controlled study of NPC-21 for kidney transplant recipients at high risk of CMV infection in the United States and Japan. Approximately 108 eligible patients will be randomized prior to first study drug administration to receive low-dose NPC 21, high-dose NPC-21, or placebo. Randomization will be stratified by region (United States or Japan)

Study Timeline

• Study First Submitted: 2020-01-09
• Study First Submitted QC: 2020-01-09
• Study First Posted: 2020-01-13
• Study Start: 2020-06-01
• Primary Completion: 2022-11-02
• Status Verified: 2023-02
• Study Completion: 2023-02-08
• Results First Submitted: 2024-04-24
• Results First Submitted QC: 2024-06-26
• Last Update Submitted: 2024-06-26
• Results First Posted: 2024-06-28
• Last Update Posted: 2024-06-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 87

Inclusion Criteria

1. Male or female patients 18 to 75 years of age in the United States or 20 to 75 years of age in Japan at the time of obtaining informed consent.
2. Patients must be CMV seronegative pre-transplant and scheduled to receive or have received (within 7 days prior to first study drug administration) a first kidney transplant from a CMV seropositive donor.
3. Patients must be willing and able to give written informed consent for participation in the study.
4. Patients must be eligible to undergo kidney transplantation from a living or deceased donor, as per institutional standards.
5. Patients must agree with contraception by using appropriate contraceptive measures.

Exclusion Criteria

1. Patients who have received a previous solid organ transplantation or hematopoietic stem cell transplantation.

2. Patients who receive a multi-organ transplant.

3. Patients who have CMV disease or CMV viremia at Screening.

4. Patients who have a positive donor-specific antibody within 90 days prior to Randomization confirmed via medical records.

5. Patients whose body weight is more than 120 kg at Screening.

6. Patients who have received the following anti-CMV therapy within 7 days prior to Randomization and/or plan to receive the following anti-CMV therapy during the study:

   ・ Anti-CMV agents (eg, foscarnet, ganciclovir, valganciclovir, letermovir, high dose acyclovir, high dose valacyclovir, high dose famciclovir, or cidofovir).

   Note: The use of anti-CMV agents per local standard of care during the Rescue Phase of the study is permitted.

   Note: The use of anti-herpes simplex virus and anti-varicella zoster virus prophylaxis for at-risk patients is recommended (as long as the doses are below the one specified above).

7. Patients who have received the following therapy within 28 days prior to Randomization and/or plan to receive the following anti-CMV therapy during the study:

   • CMV hyperimmune globulin (eg, CytoGam).
   • Intravenous immunoglobulin.
   • Plasmapheresis (receipt prior to first study drug administration is acceptable).

8. Patients with a history of a serious drug allergy to proteins, immunoglobulins, transfusions, or vaccines or any excipient of the NPC-21 formulation.

9. Patients with severe hepatic insufficiency at Screening (eg, Child-Pugh Class C).

10. Patients with active and untreated hepatitis B virus or hepatitis C virus, as documented as part of the pre-transplant screening.

11. Patients with known human immunodeficiency virus infection, based on medical records serology.

12. Patients with any uncontrolled infection at Randomization or a history of serious and uncontrolled infection within 6 months prior to Randomization.

13. Patients who are pregnant or lactating.

14. Patients with a history of malignancy within 5 years prior to Randomization other than curatively treated in situ cervical carcinoma, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma.

15. Patients with a history of alcohol or drug abuse or dependence within 1 year prior to Randomization that, in the opinion of the Investigator, would preclude study participation.

16. Patients who have previously participated in this study or any other study involving NPC-21.

17. Patients who have previously participated or are currently participating in any study involving the administration of a CMV vaccine or another CMV investigational agent.

18. Patients who have participated in another interventional clinical study and received another investigational product (ie, not approved by the Food and Drug Administration in the United States or the Ministry of Health, Labour and Welfare in Japan) within 90 days before Randomization.

19. Patients who are unable or unwilling, in the opinion of the Investigator, to comply with the protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
NPC-21 Low dose	NPC-21 Low dose	NPC-21 (6mg/kg) will be administered
NPC-21 High dose	NPC-21 High dose	NPC-21 (12mg/kg) will be administered
NPC-21 Placebo	NPC-21 Placebo	Placebo (normal saline) will be administered

Primary Outcome Measures

Name	Time	Method
Incidence of CMV Disease or CMV Viremia	16 weeks	The proportion of patients with CMV disease (CMV syndrome or tissue-invasive CMV disease) or CMV viremia (defined as the detection of 250 IU/mL in plasma measured by PCR analysis in central laboratory or meets the local criteria for CMV viremia measured by PCR analysis or antigenemia testing) per total patients through 16 weeks from first study drug administration.; The non-responders include all patients who develop CMV disease or CMV viremia and patients who discontinue from the study in the absence of CMV disease or CMV viremia.

Secondary Outcome Measures

Name	Time	Method
Incidence of CMV Disease	28 weeks	The proportion of patients with CMV disease
Incidence of CMV Viremia	28 weeks	The proportion of patients with CMV viremia.
Incidence of CMV Disease or CMV Viremia	28 weeks	The proportion of patients with CMV disease or CMV viremia. The non-responders include all patients who develop CMV disease or CMV viremia and patients who discontinue from the study in the absence of CMV disease or CMV viremia.
Time to Detectable CMV Disease or CMV Viremia	28 weeks	The count and proportion of patients experiencing event and censored will be summarized by treatment group.
Time to Detectable CMV Disease	28 weeks	The count and proportion of patients experiencing event and censored will be summarized by treatment group.
Time to Detectable CMV Viremia	28 weeks	The count and proportion of patients experiencing event and censored will be summarized by treatment group.

Trial Locations

Locations (28)

Augusta University Medical Center; 🇺🇸 Augusta, Georgia, United States

University of Texas Southwestern; 🇺🇸 Dallas, Texas, United States

Washington University School of Medicine; 🇺🇸 Saint Louis, Missouri, United States

Research site_206; 🇯🇵 Kobe, Hyogo, Japan

Research site_212; 🇯🇵 Kumamoto-shi, Kumamoto, Japan

Cleveland Clinic; 🇺🇸 Cleveland, Ohio, United States

Research site_202; 🇯🇵 Toyoake, Aichi, Japan

Research site_201; 🇯🇵 Nagoya, Aichi, Japan

The Christ Hospital; 🇺🇸 Cincinnati, Ohio, United States

University of Cincinnati College of Medicine; 🇺🇸 Cincinnati, Ohio, United States

Research site_213; 🇯🇵 Hachioji-shi, Tokyo, Japan

Piedmont Healthcare; 🇺🇸 Atlanta, Georgia, United States

Mayo Clinic - Scottsdale; 🇺🇸 Phoenix, Arizona, United States

University of Minnesota; 🇺🇸 Minneapolis, Minnesota, United States

University of Nebraska Medical Center; 🇺🇸 Omaha, Nebraska, United States

California Institute of Renal Research; 🇺🇸 La Mesa, California, United States

Renal Disease Research Institute; 🇺🇸 Dallas, Texas, United States

University of Wisconsin - Madison; 🇺🇸 Madison, Wisconsin, United States

Research site_217; 🇯🇵 Kawasaki-shi, Kanagawa, Japan

Research site_204; 🇯🇵 Nagakute, Aichi, Japan

Research site_205; 🇯🇵 Nishinomiya, Hyogo, Japan

Research site_215; 🇯🇵 Tomigusuku-shi, Okinawa, Japan

Research site_211; 🇯🇵 Osaka-shi, Osaka, Japan

Research site_214; 🇯🇵 Osaka-shi, Osaka, Japan

Research site_216; 🇯🇵 Osaka-shi, Osaka, Japan

Research site_203; 🇯🇵 Shimotsuke, Tochigi, Japan

Research site_208; 🇯🇵 Suita, Osaka, Japan

University of Michigan; 🇺🇸 Ann Arbor, Michigan, United States